DK95291A - Rekombinante dna-molekyler - Google Patents

Rekombinante dna-molekyler Download PDF

Info

Publication number
DK95291A
DK95291A DK095291A DK95291A DK95291A DK 95291 A DK95291 A DK 95291A DK 095291 A DK095291 A DK 095291A DK 95291 A DK95291 A DK 95291A DK 95291 A DK95291 A DK 95291A
Authority
DK
Denmark
Prior art keywords
dna molecules
polypeptides
carrier protein
human
processes
Prior art date
Application number
DK095291A
Other languages
Danish (da)
English (en)
Other versions
DK95291D0 (da
Inventor
Emerald Martin Spencer
Carol Talkingtonverser
Original Assignee
Biogrowth Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23115154&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK95291(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogrowth Inc filed Critical Biogrowth Inc
Publication of DK95291D0 publication Critical patent/DK95291D0/da
Publication of DK95291A publication Critical patent/DK95291A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK095291A 1988-12-22 1991-05-21 Rekombinante dna-molekyler DK95291A (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29025088A 1988-12-22 1988-12-22
PCT/US1989/005791 WO1990006950A1 (en) 1988-12-22 1989-12-21 Recombinant dna molecules, hosts, processes and human somatomedin carrier protein-like polypeptides

Publications (2)

Publication Number Publication Date
DK95291D0 DK95291D0 (da) 1991-05-21
DK95291A true DK95291A (da) 1991-08-16

Family

ID=23115154

Family Applications (1)

Application Number Title Priority Date Filing Date
DK095291A DK95291A (da) 1988-12-22 1991-05-21 Rekombinante dna-molekyler

Country Status (14)

Country Link
EP (2) EP0451194B1 (es)
JP (2) JPH04503352A (es)
KR (1) KR910700261A (es)
AT (1) ATE155793T1 (es)
AU (1) AU4836890A (es)
CA (1) CA2006322C (es)
DE (1) DE68928203T2 (es)
DK (1) DK95291A (es)
ES (1) ES2107422T3 (es)
GR (1) GR3025094T3 (es)
HK (1) HK1000826A1 (es)
IL (1) IL92816A0 (es)
WO (1) WO1990006950A1 (es)
ZA (1) ZA899832B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
US5198340A (en) * 1991-01-17 1993-03-30 Genentech, Inc. Assay for free igf-i, igf-ii, and gh levels in body fluids
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US5643867A (en) * 1992-08-26 1997-07-01 Celtrix Pharmaceuticals, Inc. Method for treating catabolic conditions
EP0800530A4 (en) * 1994-07-20 1998-12-02 Celtrix Pharma IGF / IGFBP COMPLEX FOR PROMOTING BONE TRAINING AND REGULATING BONE REMODELING
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US20030069177A1 (en) 2000-05-16 2003-04-10 Genentech, Inc. Method for treating cartilage disorders
EP1141014B1 (en) 1999-01-06 2004-12-08 Genentech, Inc. Insulin-like growth factor (igf) i mutant variant
IL143834A0 (en) 1999-01-06 2002-04-21 Genentech Inc Insulin-like growth factor (igf) i mutant variants
CA2702192A1 (en) 2001-03-14 2002-09-19 Genentech, Inc. Igf antagonist peptides
US7638605B2 (en) 2003-05-01 2009-12-29 ImClone, LLC Fully human antibodies directed against the human insulin-like growth factor-1 receptor
PT2274978E (pt) 2003-09-12 2015-07-09 Ipsen Biopharmaceuticals Inc Métodos para tratamento da deficiência do fator de crescimento de tipo insulina i (igf-i)
CA2541015A1 (en) 2003-10-03 2005-04-14 Genentech, Inc. Igf binding proteins
CA2612449A1 (en) 2005-06-17 2006-12-28 Imclone Systems Incorporated Receptor antagonists for treatment of metastatic bone cancer
CN101484587B (zh) 2006-02-03 2014-02-12 英克隆有限责任公司 Igf-ir拮抗剂作为辅药用于前列腺癌的治疗
KR20200097679A (ko) 2017-09-11 2020-08-19 샤이어 휴먼 지네틱 테라피즈 인크. 만성 폐 질환 치료를 위한 방법 및 조성물
MX2023004426A (es) 2020-10-19 2023-08-04 Oak Hill Bio Ltd Composiciones adecuadas para su uso en neonatos.
WO2023139115A1 (en) 2022-01-19 2023-07-27 Oak Hill Bio Limited Compositions and methods for reducing oxidation of igf‐1/igfbp
WO2023242440A1 (en) 2022-06-17 2023-12-21 Oak Hill Bio Limited Treament of lungs in infants
WO2023242439A1 (en) 2022-06-17 2023-12-21 Oak Hill Bio Limited Vascular stabilisation (preterm infants)
WO2023242442A1 (en) 2022-06-17 2023-12-21 Oak Hill Bio Limited Method of maturing/differentiating neurons and/or modulating the vagus nerve

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68218A (en) * 1983-03-23 1985-12-31 Univ Ramot Compositions for cartilage repair comprising embryonal chondrocytes
US4738921A (en) * 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
CA1322714C (en) * 1986-11-14 1993-10-05 Harry N. Antoniades Wound healing and bone regeneration
US4885163A (en) * 1987-02-24 1989-12-05 Eli Lilly And Company Topical use of IGF-II for wound healing
WO1989008666A1 (en) * 1988-03-17 1989-09-21 Novo-Nordisk A/S Heparin-binding proteins, dna cuding for them, processes for producing them as well as therapeutic preparations containing them
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
ATE132164T1 (de) * 1988-04-12 1996-01-15 Amgen Boulder Inc Verfahren zur steigerung und zur hemmung der wirkung eines insulinähnlichen wachstumfaktors

Also Published As

Publication number Publication date
GR3025094T3 (en) 1998-01-30
KR910700261A (ko) 1991-03-14
AU4836890A (en) 1990-07-10
IL92816A0 (en) 1990-09-17
WO1990006950A1 (en) 1990-06-28
EP0375438A2 (en) 1990-06-27
EP0375438A3 (en) 1992-03-25
ATE155793T1 (de) 1997-08-15
ES2107422T3 (es) 1997-12-01
ZA899832B (en) 1990-10-31
EP0451194B1 (en) 1997-07-23
DE68928203T2 (de) 1998-01-15
CA2006322A1 (en) 1990-06-22
EP0451194A1 (en) 1991-10-16
EP0451194A4 (en) 1992-09-02
JPH11236400A (ja) 1999-08-31
CA2006322C (en) 2000-08-01
DK95291D0 (da) 1991-05-21
JPH04503352A (ja) 1992-06-18
HK1000826A1 (en) 1998-05-01
DE68928203D1 (de) 1997-09-04

Similar Documents

Publication Publication Date Title
DK95291A (da) Rekombinante dna-molekyler
DK677688A (da) Humane somatomedinbaererproteinunderenheder og fremgangsmaade til fremstilling af saadanne
IL92257A0 (en) Binding proteins for insulin-like growth factors,pharmaceutical compositions containing them and dna fragments encoding them
DE3783191D1 (de) Verfahren und mittel zur herstellung eines proteins mit der gleichen igg-spezifizitaet wie protein g.
FI102768B1 (fi) Hybridi-DNA-molekyyli ja menetelmä fibronektiiniä sitovan proteiinin valmistamiseksi
DE68926888D1 (de) Verfahren zur Herstellung von sekretierten Rezeptoranalogen
WO1995021919A3 (en) Protein having tpo activity
FI103892B1 (fi) Rekombinantti-DNA-molekyyli, joka koodaa polypeptidiä/proteiinia, jolla on oleellisesti vaskulaaristen antikoaguloivien proteiinien biologiset ominaisuudet sekä niiden valmistus
DE3855084D1 (de) Herstellung und Reinigung eines Proteins, das mit einem Bindungsprotein fusioniert ist
NO177570C (no) Fremgangsmåte ved fremstilling av peptider med fibronektinbindende egenskaper, mikroorganisme og DNA-sekvens som koder for peptider med fibronektinbindende egenskaper
EP0546074A4 (en) Genetic material encoding igfbp-5
FI921600A (fi) Bjoerkpollenallergen p14 foer diagnos och behandling av allergiska sjukdomar.
PT98804A (pt) Processo de preparacao de igfbp-4 ou um fragmento da mesma
EP0261403A3 (de) Polypeptide des Rhinovirusstammes HRV89 sowie die hierfür codierenden DNA-Moleküle
SE8801723D0 (sv) Fibronectin binding protein as well as its preparation
WO1995008628A3 (en) Nucleic acids encoding merosin, merosin fragments and uses thereof
DK595187D0 (da) Minactivin og fremgangsmaade til fremstilling deraf
IL78278A0 (en) Process for the production of polypeptides,dna sequence encoding desired polypeptide human somatomedin c polypeptide and recombinant dna molecules
Spencer et al. Uses for antibodies which bind to human somatomedin carrier protein subunits
MX9504057A (es) Proteina que tiene actividad tpo.